PVLA
Palvella Therapeutics, Inc. trades as PVLA and has a market capitalization of $1.44 B, making it the #2360 largest US-listed company by market value. In its fiscal 2023 annual report the company posted revenue of $42.81M, up 65.3% from the prior year and net income of -$41.72M. This page tracks Palvella Therapeutics, Inc. through 774 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years Palvella Therapeutics, Inc.'s revenue grew from $5.37M to $42.81M, a compound annual growth rate of 26.0%. Net profit margin expanded from -391.0% to 43.7% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-20 |
| Major company event | 8-K | 2026-05-20 |
| Major company event | 8-K | 2026-05-15 |
| Major company event | 8-K | 2026-05-13 |
| Major company event | 8-K | 2026-05-07 |
| Quarterly report | 10-Q | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-30 |
The largest companies sharing Palvella Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Palvella Therapeutics, Inc. (PVLA) has a market capitalization of $1.44 B as of 2026-06-10, ranking #2360 among US-listed companies.
Palvella Therapeutics, Inc. reported revenue of $42.81M for fiscal year 2023, an increase of 65.3% year over year.
In its latest fiscal year Palvella Therapeutics, Inc. reported a net loss of $41.72M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.